22 Mar 2017 09:00
22nd March 2017
Â
Avacta Group plc
("Avacta" or "the Group" or "the Company")
Â
Avacta to present at the UK Investor Show
Â
Â
Avacta Group plc (AIM: AVCT), the developer of Affimer® biotherapeutics and research reagents, is pleased to announce that its Chief Executive, Alastair Smith, will be presenting at the UK Investor Show on 1s t April 2017 at the QE2 Centre, Westminster, London.
Â
The UK Investor Show is the largest UK stock market event with 3,000 investors expected to attend.
Â
Members of Avacta Group's management team will be at stand 37 during the day and Alastair Smith will be presenting at 16:00 in the Winnifrith-Britten room.
Â
For more information, including registration details, please visit:
Â
www.ukinvestorshow.com
Â
Â
ENDS
Â
Â
Notes to Editors
Â
For further information from Avacta Group plc, please contact:
Â
Avacta Group plc Alastair Smith, Chief Executive Officer Tony Gardiner, Chief Financial Officer  | Tel: +44 (0) 844 414 0452 www.avacta.com |
finnCap Ltd Geoff Nash / Giles Rolls - Nominated Adviser Tim Redfern / Alice Lane - Corporate Broking  WG Partners David Wilson Nigel Barnes Claes Spang  | Tel: +44 (0) 207 220 0500 www.finncap.com   Tel: +44 (0) 203 705 9318 Tel: +44 (0) 203 705 9217 www.wgpartners.co.uk   |
Zyme Communications (Trade and Regional Media) Katie Odgaard  FTI Consulting (Financial Media and IR) Simon Conway / Natalie Garland-Collins | Tel: +44 (0)7787 502 947 katie.odgaard@zymecommunications.com  Tel: +44 (0) 203 727 1000 avacta@fticonsulting.com |
Â
Â
About Avacta Group plc (www.avacta.com)
Avacta's principal focus is on its proprietary Affimer® technology which is a novel engineered alternative to antibodies that has wide application in Life Sciences for diagnostics, therapeutics and general research and development.
Â
Antibodies dominate markets worth in excess of $50bn despite their shortcomings. Affimer technology has been designed to address many of these negative performance issues, principally; the time taken to generate new antibodies, the reliance on an animal's immune response, poor specificity in many cases, and batch to batch variability. Affimer technology is based on a small protein that can be quickly generated to bind with high specificity and affinity to a wide range of protein targets.
Â
Avacta has a pre-clinical biotech development programme with an in-house focus on immuno-oncology and bleeding disorders as well as partnered development programmes. Avacta is also commercialising non-therapeutic Affimer reagents through licensing to developers of life sciences research tools and diagnostics.